---
title: "Top 5 美股千億以上公司漲跌幅（2月23日）"
description: "阿尼科伊格爾礦業 (AEM) 涨 5.36%，成交额 6.4 亿美元，年内累计涨 41.9%。 禮來 (LLY) 涨 4.86%，成交额 50.1 亿美元，年内累计跌 1.3%。 諾和諾德公司 (NVO) 跌 16.43%，成交额 39.4 亿美元，年内累计跌 22.1%。 IBM(IBM) 跌 13.15%，成交额 44.8 亿美元，年内累计跌 24.2%。"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/276650697.md"
published_at: "2026-02-23T22:00:51.000Z"
---

# Top 5 美股千億以上公司漲跌幅（2月23日）

> 阿尼科伊格爾礦業 (AEM) 涨 5.36%，成交额 6.4 亿美元，年内累计涨 41.9%。 禮來 (LLY) 涨 4.86%，成交额 50.1 亿美元，年内累计跌 1.3%。 諾和諾德公司 (NVO) 跌 16.43%，成交额 39.4 亿美元，年内累计跌 22.1%。 IBM(IBM) 跌 13.15%，成交额 44.8 亿美元，年内累计跌 24.2%。

納斯達克綜合指數跌 1.13%，年内累計跌 2.6%；標普 500 指數跌 1.04%，年内累計跌 0.1%；道瓊斯指數跌 1.66%，年内累計涨 1.5%。

阿尼科伊格爾礦業 (AEM) 涨 5.36%，成交额 6.4 亿美元，年内累计涨 41.9%。

禮來 (LLY) 涨 4.86%，成交额 50.1 亿美元，年内累计跌 1.3%。

諾和諾德公司 (NVO) 跌 16.43%，成交额 39.4 亿美元，年内累计跌 22.1%。

IBM(IBM) 跌 13.15%，成交额 44.8 亿美元，年内累计跌 24.2%。

### Related Stocks

- [AEM.US - 阿尼科伊格爾礦業](https://longbridge.com/zh-HK/quote/AEM.US.md)
- [LLY.US - 禮來](https://longbridge.com/zh-HK/quote/LLY.US.md)
- [GLW.US - 康寧](https://longbridge.com/zh-HK/quote/GLW.US.md)
- [SCCO.US - 南方銅業](https://longbridge.com/zh-HK/quote/SCCO.US.md)
- [ABT.US - 雅培](https://longbridge.com/zh-HK/quote/ABT.US.md)
- [NVO.US - 諾和諾德公司](https://longbridge.com/zh-HK/quote/NVO.US.md)
- [IBM.US - IBM](https://longbridge.com/zh-HK/quote/IBM.US.md)
- [APP.US - AppLovin](https://longbridge.com/zh-HK/quote/APP.US.md)
- [COF.US - 第一資本金融](https://longbridge.com/zh-HK/quote/COF.US.md)
- [AXP.US - 美國運通](https://longbridge.com/zh-HK/quote/AXP.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| IBM Stock Is Trending After Crating 13% And Claude-Maker Anthropic Is The Reason Why: Here's What Happened | IBM shares fell 13% after Anthropic's Claude Code AI tool raised concerns about potential disruption to IBM's legacy mai | [Link](https://longbridge.com/zh-HK/news/276674951.md) |
| Key facts: Novo Nordisk Faces Challenges with CagriSema; $35B M&A Plans | J.P. Morgan analysts raised concerns about CagriSema's underperformance, which may affect demand and long-term sales for | [Link](https://longbridge.com/zh-HK/news/276670594.md) |
| Puzo Michael J Has $320,000 Stock Position in Novo Nordisk A/S $NVO | Puzo Michael J significantly reduced its stake in Novo Nordisk A/S (NYSE:NVO) by 86.9% in Q3, now holding 5,775 shares v | [Link](https://longbridge.com/zh-HK/news/276447697.md) |
| GLP-1 Anti-Obesity U.S. Drug Market In Four Charts | UBS analysts, led by Matthew Weston, have analyzed trends in the U.S. GLP-1 anti-obesity drug market, focusing on new-to | [Link](https://longbridge.com/zh-HK/news/276280378.md) |
| Novo Nordisk slump wipes out last Wegovy-era gains after trial setback | Novo Nordisk shares plummeted over 15% following a trial setback for its obesity drug CagriSema, which failed to match t | [Link](https://longbridge.com/zh-HK/news/276594064.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。